Skip to main content
Biocorp logo

Biocorp — Investor Relations & Filings

Ticker · ALCOR ISIN · FR0012788065 LEI · 969500TKUAME6031UQ32 PA Manufacturing
Open in API
Filings indexed 235 across all filing types
Latest filing 2019-03-07 Share Issue/Capital Cha…
Country FR France
Listing PA ALCOR

About Biocorp

https://biocorpsys.com

Biocorp designs, develops, and manufactures medical devices and drug delivery systems for the pharmaceutical industry. The company specializes in combining precision engineering with connected technologies to improve patient treatment adherence and outcomes. Its portfolio includes both connected and non-connected devices, such as smart caps for inhalers (Inspair), pen injectors, and systems for drug reconstitution and safety. Biocorp manages the entire value chain, from research and development to manufacturing and final packaging, leveraging its expertise in plastics processing and advanced technological innovation. Since October 2023, Biocorp has been a subsidiary of Novo Nordisk.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 1% confidence The document is a press release titled "BIOCORP annonce le succès de son augmentation de capital par placement privé d'un montant de 1 M€" (BIOCORP announces the success of its capital increase by private placement for an amount of €1M). It details the issuance of new shares and convertible bonds, the amount raised (€2 million total), the use of proceeds, and the resulting changes in shareholding structure. This content directly relates to fundraising, financing activities, and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (over 10,000 characters), confirming it is the primary announcement, not just a brief RPA.
2019-03-07 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document explicitly announces two concurrent financing activities: 'lancement d'une augmentation de capital par placement privé d'un montant d'environ 1 M€' (launch of a capital increase via private placement) and 'l'émission d'obligations convertibles pour un montant de 1 M€' (issuance of convertible bonds). The core subject matter is raising capital through equity and debt instruments. This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although it mentions the results will be announced later, the document itself details the structure and purpose of the financing operations, making it a primary financing announcement rather than just a 'Report Publication Announcement' (RPA).
2019-03-06 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release dated February 21st, 2019, announcing a partnership between BIOCORP and DreaMed Diabetes regarding an AI system for diabetes treatment compliance. It details product integration (Mallya and DreaMed AdvisorTM Pro) and future clinical trials. This type of announcement, detailing strategic business developments, partnerships, or product milestones outside of mandatory financial reporting periods (like 10-K or IR), typically falls under general corporate news or regulatory filings. Since it is a specific announcement of a business development rather than a general regulatory filing (RNS) or a specific financial report, and it doesn't fit the definitions for M&A (TAR), Capital (CAP), or Director changes (MANG), the most appropriate category is 'Regulatory Filings' (RNS) as a general announcement, or potentially 'LTR' if the partnership implied a significant legal/regulatory step, but RNS serves as the best general announcement fallback for non-standard corporate news releases that aren't earnings or dividend related. Given the context of a press release announcing a strategic collaboration, RNS is the most suitable general classification.
2019-02-21 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document announces a strategic partnership between BIOCORP and DreaMed Diabetes regarding an AI-based diabetes management solution. It details the collaboration, describes the products involved (Mallya and DreaMed Advisor), includes quotes from management, and provides 'About Us' sections for both companies. This content structure—announcing a significant business development, partnership, or strategic move—is characteristic of a press release or a general regulatory announcement that doesn't fit the specific financial reporting categories (like 10-K, ER, IR, etc.). Since it is a formal announcement of a business event, and it is not a specific financial report, the most appropriate general category is Regulatory Filings (RNS), which serves as a catch-all for significant, non-standardized corporate disclosures.
2019-02-21 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document announces a strategic partnership and agreement between two companies, BIOCORP and AgaMatrix, regarding distribution rights and co-development activities for a medical device (Mallya pen cap). This type of announcement, detailing business agreements, strategic alliances, and potential revenue generation, does not fit the specific definitions for financial reports (10-K, IR, ER), governance documents (CGR, DEF 14A), or shareholder actions (AGM-R, DVA). It is a general business update concerning future operations and market strategy. Since it is not a formal regulatory filing like a 10-K or a specific financial release, and it details a significant business transaction (partnership/distribution rights), it most closely aligns with a general corporate announcement. Given the provided options, the most appropriate category for a significant business development announcement that isn't explicitly covered by the other codes (like M&A (TAR) or Financing (CAP)) is the general Regulatory Filings (RNS) category, which often serves as a catch-all for material non-financial news, or potentially a general announcement if RNS is strictly for exchange filings. However, in the context of corporate filings, major partnership announcements are often disclosed via regulatory channels. Since there is no specific 'Partnership Announcement' code, RNS is the best fit as a general disclosure mechanism for material news.
2019-02-18 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document announces a strategic partnership and distribution agreement between BIOCORP and AgaMatrix concerning medical devices (Mallya sensor and glucose monitoring solutions). This type of announcement, detailing business development, strategic alliances, and potential revenue generation from new agreements, does not fit neatly into standard periodic financial reports (10-K, IR, ER) or specific corporate actions like dividends or director dealings. It is a significant business update that falls under general corporate news. Since there is no specific category for 'Partnership Announcement' or 'Business Development,' the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for significant, non-standard corporate announcements that must be disclosed.
2019-02-18 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.